We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

41 hedge funds and large institutions have $20M invested in vTv Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

0.32% more ownership

Funds ownership: 0.95% → 1.27% (+0.32%)

7% less funds holding

Funds holding: 44 → 41 (-3)

9% less capital invested

Capital invested by funds: $22.1M → $20M (-$2.05M)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
41
Holders Change
-3
Holders Change %
-6.82%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
GMT Capital
Georgia
+$5.75M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.81M
3
RA
Royce & Associates
New York
+$845K
4
JP Morgan Chase
JP Morgan Chase
New York
+$719K
5
CWG
C WorldWide Group
Denmark
+$599K

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$1.04M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$827K
3
CS
Candriam SCA
Luxembourg
-$541K
4
SM
Sabby Management
Florida
-$267K
5
Renaissance Technologies
Renaissance Technologies
New York
-$215K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$24K +$27.7K +113 +353%
PAM
27
Panagora Asset Management
Massachusetts
$20K -$1.47K -6 -5%
AIG
28
American International Group
New York
$18K -$1.47K -6 -5%
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$18K – – –
Barclays
30
Barclays
United Kingdom
$8K – – –
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$6.22K -$1.22K -5 -12%
Wells Fargo
32
Wells Fargo
California
$6K +$245 +1 +3%
Manulife (Manufacturers Life Insurance)
33
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K -$9.06K -37 -55%
AG
34
Advisor Group
Arizona
$5K +$2.45K +10 +50%
Legal & General Group
35
Legal & General Group
United Kingdom
$4K – – –
UBS Group
36
UBS Group
Switzerland
$4K +$1.71K +7 +39%
Bank of America
37
Bank of America
North Carolina
$2K -$1.71K -7 -33%
AIP
38
Ameritas Investment Partners
Nebraska
$2K – – –
Ameriprise
39
Ameriprise
Minnesota
– -$1.04M -4,323 Closed
CS
40
Candriam SCA
Luxembourg
– -$541K -2,250 Closed
SM
41
Sabby Management
Florida
– -$267K -1,113 Closed
Creative Planning
42
Creative Planning
Kansas
– -$114K -475 Closed
TA
43
Teachers Advisors
New York
– -$51K -211 Closed
Parallax Volatility Advisers
44
Parallax Volatility Advisers
California
– -$7K -28 Closed
Citigroup
45
Citigroup
New York
– -$4K -18 Closed
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
– -$490 -2 Closed
1
2

VTVT Hedge Fund Activity: Q1 2018 in Review

41 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2018, worth a combined $20M — down 9.3% from $22.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of VTVT and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 13 added.

The largest buyer was GMT Capital, opening a new position worth an estimated $5.75M. The largest seller was Ameriprise, exiting entirely with an estimated $1.04M sold.

  • 41 institutional investors held vTv Therapeutics (VTVT) as of Q1 2018, down from 44 in Q4 2017.
  • Funds reported $20M of vTv Therapeutics stock for Q1 2018, down 9.3% quarter-over-quarter.
  • 5 funds opened new vTv Therapeutics positions in Q1 2018 and 8 closed out, a net change of -3 holders.
  • The largest vTv Therapeutics buyer in Q1 2018 was GMT Capital, an estimated $5.75M added.
  • The largest vTv Therapeutics seller in Q1 2018 was Ameriprise, an estimated $1.04M sold.

Based on aggregated 13F filings for Q1 2018.